Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited financial results of the Company (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026

CSD/SE/BM-NOTICE/ 2026-27 Date: October 29, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Board Meeting Intimation under Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the provisions of Regulation 29 of SEBI (LODR) Regulations, 2015, we wish to inform that the Meeting of the Board of Directors of Suven Life Sciences Limited is scheduled to be held on Thursday, 5th November, 2026 inter alia to consider and approve the unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. In terms of the Code of Conduct for Prohibition of Insider Trading in Securities of the Company, we hereby inform that the Trading Window was closed from 01st October, 2026 and shall remain closed up to 48 hours after the declaration of the unaudited Financial Results of the Company. This is for your information and records. Thanking you, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary & Compliance Officer Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I Road No.5 | Avenue 7 Banjara Hills I Hyderabad – 500034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: +91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com